Benzinga | Oct 14, 2021 07:36AM EDT

SVB Leerink Initiates Coverage On Monte Rosa Therapeutics with Market Perform Rating, Announces Price Target of $20

SVB Leerink analyst Andrew Berens initiates coverage on Monte Rosa Therapeutics (NASDAQ:GLUE) with a Market Perform rating and announces Price Target of $20.